<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?covid-19-tdm?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLoS ONE</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1932-6203</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8791494</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pone.0262953</article-id>
    <article-id pub-id-type="publisher-id">PONE-D-21-38076</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Research Article</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and life sciences</subject>
        <subj-group>
          <subject>Molecular biology</subject>
          <subj-group>
            <subject>Molecular biology techniques</subject>
            <subj-group>
              <subject>Cloning</subject>
              <subj-group>
                <subject>DNA cloning</subject>
                <subj-group>
                  <subject>Shotgun Sequencing</subject>
                </subj-group>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and analysis methods</subject>
        <subj-group>
          <subject>Molecular biology techniques</subject>
          <subj-group>
            <subject>Cloning</subject>
            <subj-group>
              <subject>DNA cloning</subject>
              <subj-group>
                <subject>Shotgun Sequencing</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Molecular Biology Techniques</subject>
            <subj-group>
              <subject>Sequencing Techniques</subject>
              <subj-group>
                <subject>Shotgun Sequencing</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Molecular Biology Techniques</subject>
          <subj-group>
            <subject>Sequencing Techniques</subject>
            <subj-group>
              <subject>Shotgun Sequencing</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Genomics</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Computer and Information Sciences</subject>
        <subj-group>
          <subject>Data Management</subject>
          <subj-group>
            <subject>Data Processing</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Database and Informatics Methods</subject>
          <subj-group>
            <subject>Biological Databases</subject>
            <subj-group>
              <subject>Mutation Databases</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Mutation</subject>
            <subj-group>
              <subject>Mutation Databases</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Genomics</subject>
            <subj-group>
              <subject>Metagenomics</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Molecular Biology Techniques</subject>
            <subj-group>
              <subject>Sequencing Techniques</subject>
              <subj-group>
                <subject>Nucleotide Sequencing</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Molecular Biology Techniques</subject>
          <subj-group>
            <subject>Sequencing Techniques</subject>
            <subj-group>
              <subject>Nucleotide Sequencing</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Computational Biology</subject>
          <subj-group>
            <subject>Genome Analysis</subject>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Genomics</subject>
            <subj-group>
              <subject>Genome Analysis</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Computational Techniques</subject>
          <subj-group>
            <subject>Computational Pipelines</subject>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ASPICov: An automated pipeline for identification of SARS-Cov2 nucleotidic variants</article-title>
      <alt-title alt-title-type="running-head">ASPICov: An automated pipeline for identification of SARS-Cov2 nucleotidic variants</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2967-8670</contrib-id>
        <name>
          <surname>Tilloy</surname>
          <given-names>Valentin</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Cuzin</surname>
          <given-names>Pierre</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3748-4179</contrib-id>
        <name>
          <surname>Leroi</surname>
          <given-names>Laura</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Guérin</surname>
          <given-names>Emilie</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Durand</surname>
          <given-names>Patrick</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff004" ref-type="aff">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9787-1421</contrib-id>
        <name>
          <surname>Alain</surname>
          <given-names>Sophie</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff003" ref-type="aff">
          <sup>3</sup>
        </xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Centre National de Référence des Herpèsvirus, CHU Dupuytren, Limoges, France</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>UF9481 Bioinformatique, CHU Dupuytren, Limoges, France</addr-line>
    </aff>
    <aff id="aff003">
      <label>3</label>
      <addr-line>UF8843 Génomique médicale, CHU Dupuytren, Limoges, France</addr-line>
    </aff>
    <aff id="aff004">
      <label>4</label>
      <addr-line>IFREMER-IRSI-Service de Bioinformatique, Centre Bretagne, Plouzane, France</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Giorgio</surname>
          <given-names>Giurato</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>University of Salemo, ITALY</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>valentin.tilloy@unilim.fr</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>26</day>
      <month>1</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>26</day>
      <month>1</month>
      <year>2022</year>
    </pub-date>
    <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
    <volume>17</volume>
    <issue>1</issue>
    <elocation-id>e0262953</elocation-id>
    <history>
      <date date-type="received">
        <day>1</day>
        <month>12</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>28</day>
        <month>12</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 Tilloy et al</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Tilloy et al</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pone.0262953.pdf"/>
    <abstract>
      <p>ASPICov was developed to provide a rapid, reliable and complete analysis of NGS SARS-Cov2 samples to the biologist. This broad application tool allows to process samples from either capture or amplicon strategy and Illumina or Ion Torrent technology. To ensure FAIR data analysis, this Nextflow pipeline follows nf-core guidelines and use Singularity containers. Pipeline is implemented and available at <ext-link xlink:href="https://gitlab.com/vtilloy/aspicov" ext-link-type="uri">https://gitlab.com/vtilloy/aspicov</ext-link>.</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution>Santé Publique France</institution>
        </funding-source>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2967-8670</contrib-id>
          <name>
            <surname>Tilloy</surname>
            <given-names>Valentin</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <award-group id="award002">
        <funding-source>
          <institution>Région Nouvelle-Aquitaine</institution>
        </funding-source>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2967-8670</contrib-id>
          <name>
            <surname>Tilloy</surname>
            <given-names>Valentin</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <funding-statement>This work was supported by Santé Publique France and Région Nouvelle-Aquitaine.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="1"/>
      <table-count count="0"/>
      <page-count count="5"/>
    </counts>
    <custom-meta-group>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>All relevant data are within the paper and its <xref rid="sec013" ref-type="sec">Supporting Information</xref> files.</meta-value>
      </custom-meta>
      <custom-meta id="outbreaks">
        <meta-name>Outbreaks</meta-name>
        <meta-value>COVID-19</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>All relevant data are within the paper and its <xref rid="sec013" ref-type="sec">Supporting Information</xref> files.</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>Whole-genome sequencing (WGS) is used for clinical surveillance of SARS-Cov2 in order to detect emerging variants especially variants of interest (VOI) or variants of concern (VOC), to facilitate epidemiological studies and to anticipate possible therapeutic/vaccinal escape.</p>
    <p>Two main library sequencing preparation methods are used according to the context and sample origin: shotgun metagenomics and target enrichment. Various ways are undertaken such as transcriptome sequencing or combination of strategies (hybrid capture enrichment, …) depending on goals and context [<xref rid="pone.0262953.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0262953.ref002" ref-type="bibr">2</xref>].</p>
    <p>Shotgun metagenomics method is used to capture SARS-Cov2 sequences by hybridization from a highly concentrated sample. Target enrichment or amplicon strategy is often chosen to amplify and detect SARS-Cov2 at low concentrations such as in wastewaters and some particular samples (stools, blood, end-infection steps samples, …). It is also important to consider NGS sequencing platform which will not provide the same sets of data and/or which are optimized for a particular strategy library kit.</p>
    <p>In order to cover a large range of sequencing technologies and handle all parameters of our analysis we developed ASPICov, a pipeline able to identify whole genome variations at the nucleotide or amino-acid level in samples using a reference sequence. This pipeline is a multistep Nextflow [<xref rid="pone.0262953.ref003" ref-type="bibr">3</xref>] pipeline able to process raw-reads sequences into usable information such as quality reports, VCF files, sequence consensus and plots (variants and coverage).</p>
  </sec>
  <sec id="sec002">
    <title>Material and methods</title>
    <sec id="sec003">
      <title>Implementation</title>
      <p>ASPICov workflow was created as a Nextflow pipeline following some of the nf-core standards requirements to setup a portable pipeline. Code wrapping the many tools used in ASPICov (see below) is written in bash and Python. Tools themselves have been integrated into ready-to-use Singularity containers [<xref rid="pone.0262953.ref004" ref-type="bibr">4</xref>]. Singularity definition files (used to build images) as well as binary images are all available for download (see below). ASPICov comes with a test data set. In such a way, users can validate the correct execution of ASPICov on their computing infrastructure after cloning the pipeline from its public Gitlab repository.</p>
    </sec>
    <sec id="sec004">
      <title>Pipeline steps and tools used</title>
      <p>The succession of genomic tools used (<xref rid="pone.0262953.g001" ref-type="fig">Fig 1</xref>) combined to an optimized computing configuration is a key for the robustness of the pipeline.</p>
      <fig position="float" id="pone.0262953.g001">
        <object-id pub-id-type="doi">10.1371/journal.pone.0262953.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>Overview of ASPICov steps and software implemented.</title>
          <p>In red: Software used, green: Option used.</p>
        </caption>
        <graphic xlink:href="pone.0262953.g001" position="float"/>
      </fig>
      <p>To facilitate the use of ASPICov and make it highly reproducible, all tools are automatically installed via pre-built singularity images available from the National Oceanographic Data Center operated by Ifremer in France; member of the Research Data Alliance (<ext-link xlink:href="https://rd-alliance.org/" ext-link-type="uri">https://rd-alliance.org</ext-link>) (<ext-link xlink:href="ftp://ftp.ifremer.fr/ifremer/dataref/bioinfo/sebimer/tools/AspiCov/" ext-link-type="ftp">ftp://ftp.ifremer.fr/ifremer/dataref/bioinfo/sebimer/tools/AspiCov/</ext-link>). These images are built from recipes available as part of the ASPICov source code (<ext-link xlink:href="https://gitlab.com/vtilloy/aspicov/-/tree/master/containers" ext-link-type="uri">https://gitlab.com/vtilloy/aspicov/-/tree/master/containers</ext-link>).</p>
    </sec>
    <sec id="sec005">
      <title>Input options</title>
      <p>ASPICov is designed to be used on Linux distribution and launched with a single command within a cluster job scheduler or locally. Project name, technology, method, path to data, references, Trimmomatic adapter and bedpe files information will be completed by users in a custom configuration file (supported by profile), according to standard Nextflow principles. To use this workflow on a computing cluster, it is necessary to provide an institute configuration file (using -c &lt;institute_config_file&gt;) in order to enable Singularity and to setup the appropriate execution settings for the environment.</p>
    </sec>
    <sec id="sec006">
      <title>Output files</title>
      <p>ASPICov generates different results organized in seven folders (<xref rid="pone.0262953.g001" ref-type="fig">Fig 1</xref>). Figures, filtered VCF, specific variant highlight and consensus files are particularly helpful for biological interpretation.</p>
    </sec>
    <sec id="sec007">
      <title>Availability</title>
      <p>ASPICov is a free and open-source pipeline available and updated on a public Gitlab repository (<ext-link xlink:href="https://gitlab.com/vtilloy/aspicov" ext-link-type="uri">https://gitlab.com/vtilloy/aspicov</ext-link>). It is provided with a quick start guide, a complete documentation describing all options available to fine tune data processing.</p>
    </sec>
    <sec id="sec008">
      <title>Dataset used to design and to validate the pipeline</title>
      <p>Wuhan strain (NC_045512 [<xref rid="pone.0262953.ref005" ref-type="bibr">5</xref>] was used as whole genome reference during pipeline validation. ASPICov has been optimized using a dataset from a single sample (Basa strain isolated from a patient with mild Covid disease at Limoges hospital) taken at different culture stages (P3, P4 and P7 passages), serially diluted (10<sup>−1</sup>, 10<sup>−2</sup>, 10<sup>−3</sup>, 10<sup>−4</sup>, 10<sup>−5</sup>, 10<sup>−6</sup> and 10<sup>−7</sup>) and processed using Thermofisher and/or Swift Ampliseq protocols, Illumina (<xref rid="pone.0262953.s001" ref-type="supplementary-material">S1 Table</xref>). We have thus determined a threshold corresponding to background noise: nucleotidic variants were considered as low quality if Phred score is below 200 or depth below 100 or allelic frequency below 0.02. Mutation(s) not retained by filters are still available in VCF files tagged ‘filter’ whereas selected mutations are tagged ‘filter-pass’.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="sec009">
    <title>Results</title>
    <sec id="sec010">
      <title>ASPICov validation</title>
      <p>We have screened ENA and SRA public databases to get a dataset of SARS-Cov2 reads coming from different labs using different strategies and sequencing technologies. Our aim was to validate ASPICov from a wide range of data. All VOC and VOI were found using ASPICov workflow, demonstrating its efficiency and accuracy (<xref rid="pone.0262953.s002" ref-type="supplementary-material">S2 Table</xref>).</p>
    </sec>
    <sec id="sec011">
      <title>ASPICov potential applications</title>
      <p>From filter optimization we were able to finely observe and intersect changes for a single sample at different culture passages.</p>
      <p>We were also able to evaluate repeatability of sequencing methods by sequencing the same library on two runs with the same sequencing technology (Ion Torrent) and also by comparing two strategies (ThermoFisher and Swift amplicons designs).</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec012">
    <title>Conclusions</title>
    <p>ASPICov pipeline is dedicated to detect and identify finely SARS-Cov2 mutations from a broad range of parameters (various samples, different sequencing approaches) with concrete applications in diagnostic and wastewater domains. In order to ensure FAIR data analysis, the workflow is built as a Nexflow pipeline, follows nf-core guidelines and use Singularity containers to wrap tool environments. Its efficiency and accuracy have been demonstrated.</p>
    <p>Due to detection of VOI/VOC and IonTorrent technology analysis, ASPICov is complementary to other pipeline such as viralrecon [<xref rid="pone.0262953.ref006" ref-type="bibr">6</xref>] and Farkas pipeline [<xref rid="pone.0262953.ref007" ref-type="bibr">7</xref>]. Conception is different allowing to have an alternative and also a contribution to the diversity of tools for whole genome covid analysis.</p>
    <p>ASPICov is regularly updated on Gitlab for special variants according to WHO publications.</p>
    <p>Several new features are currently under development, such as a global HTML report, phylogenetic analysis, integration of ONT and MGI sequencing technologies, highlight of genotype percentage, PANGO lineage determination and Nextclade/Gisaid data comparison.</p>
  </sec>
  <sec id="sec013" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pone.0262953.s001" position="float" content-type="local-data">
      <label>S1 Table</label>
      <caption>
        <title>Description of samples used in the study.</title>
        <p>(DOCX)</p>
      </caption>
      <media xlink:href="pone.0262953.s001.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0262953.s002" position="float" content-type="local-data">
      <label>S2 Table</label>
      <caption>
        <title>SARS-Cov2 variants of concern (VOC) and interest (VOI).</title>
        <p>(DOCX)</p>
      </caption>
      <media xlink:href="pone.0262953.s002.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>CHU Limoges high security lab for providing SARS-Cov2 Basa prelevements.</p>
    <p>Margaux Gaschet for help in librairies preparations.</p>
    <p>Marion Desdouits for her support.</p>
    <p>The authors acknowledge the Pôle de Calcul et de Données Marines (PCDM; <ext-link xlink:href="https://wwz.ifremer.fr/en/Research-Technology/Research-Infrastructures/Digital-infrastructures/Computation-Centre" ext-link-type="uri">https://wwz.ifremer.fr/en/Research-Technology/Research-Infrastructures/Digital-infrastructures/Computation-Centre</ext-link>) for providing DATARMOR supercomputer on which ASPICov has been developed and tested.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pone.0262953.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Chiara</surname><given-names>M</given-names></name>, <name><surname>D’Erchia</surname><given-names>AM</given-names></name>, <name><surname>Gissi</surname><given-names>C</given-names></name>, <name><surname>Manzari</surname><given-names>C</given-names></name>, <name><surname>Parisi</surname><given-names>A</given-names></name>, <name><surname>Resta</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities</article-title>. <source>Briefings in Bioinformatics</source>,. <year>2021</year><month>Mar</month><day>22</day>;<volume>22</volume>(<issue>2</issue>):<fpage>616</fpage>–<lpage>630</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bib/bbaa297</pub-id><?supplied-pmid 33279989?><pub-id pub-id-type="pmid">33279989</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0262953.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Charre</surname><given-names>C</given-names></name>, <name><surname>Ginevra</surname><given-names>C</given-names></name>, <name><surname>Sabatier</surname><given-names>M</given-names></name>, <name><surname>Regue</surname><given-names>H</given-names></name>, <name><surname>Destras</surname><given-names>G</given-names></name>, <name><surname>Brun</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of NGS-based approaches for SARS-CoV-whole genome characterisation</article-title>. <source>Virus Evolution</source>. <year>2020</year><month>Oct</month><day>5</day>;<volume>6</volume>(<issue>2</issue>):veaa075. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ve/veaa075</pub-id> eCollection 2020 Jul. <?supplied-pmid 33318859?><pub-id pub-id-type="pmid">33318859</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0262953.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Di Tommaso</surname><given-names>P</given-names></name>, <name><surname>Chatzou</surname><given-names>M</given-names></name>, <name><surname>Floden</surname><given-names>EW</given-names></name>, <name><surname>Barja</surname><given-names>PP</given-names></name>, <name><surname>Palumbo</surname><given-names>E</given-names></name>, <name><surname>Notredame</surname><given-names>C</given-names></name>. <article-title>Nextflow enables reproducible computational workflows</article-title>. <source>Nature Biotechnology</source>. <year>2017</year><month>Apr</month><day>11</day>;<volume>35</volume>(<issue>4</issue>):<fpage>316</fpage>–<lpage>319</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nbt.3820</pub-id><?supplied-pmid 28398311?><pub-id pub-id-type="pmid">28398311</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0262953.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Kurtzer</surname><given-names>GM</given-names></name>, <name><surname>Sochat</surname><given-names>V</given-names></name>, <name><surname>Bauer</surname><given-names>MW</given-names></name>. <article-title>Singularity: Scientific Containers for Mobility of Compute</article-title>. <source>PLoS One</source>; <volume>12</volume>(<issue>5</issue>): <fpage>e0177459</fpage> (<year>2017</year>). <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0177459</pub-id>
<?supplied-pmid 28494014?><pub-id pub-id-type="pmid">28494014</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0262953.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>F</given-names></name>, <name><surname>Zhao</surname><given-names>S</given-names></name>, <name><surname>Yu</surname><given-names>B</given-names></name>, <name><surname>Chen</surname><given-names>YM</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Song</surname><given-names>ZG</given-names></name>, <etal>et al</etal>. <source>A new coronavirus associated with human respiratory disease in China</source>. <year>2020</year><month>Mar</month>;<volume>579</volume>(<issue>7798</issue>):<fpage>265</fpage>–<lpage>269</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><?supplied-pmid 32015508?><pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0262953.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Patel</surname><given-names>H</given-names></name>, <name><surname>Varona</surname><given-names>S</given-names></name>, <name><surname>Monzón</surname><given-names>S</given-names></name>, <name><surname>Espinosa-Carrasco</surname><given-names>J</given-names></name>, <name><surname>Heuer</surname><given-names>ML</given-names></name>, <name><surname>Gabernet</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2021</year>). <source>nf-core/viralrecon: nf-core/viralrecon v2.1—Lead Mink (2.1). Zenodo</source>. <pub-id pub-id-type="doi">10.5281/zenodo.4957929</pub-id>.</mixed-citation>
    </ref>
    <ref id="pone.0262953.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Farkas</surname><given-names>C</given-names></name>, <name><surname>Mella</surname><given-names>A</given-names></name>., <name><surname>Turgeon</surname><given-names>M.</given-names></name>, <name><surname>Haigh</surname><given-names>JJ</given-names></name>. <article-title>A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3′ Untranslated Region (UTR) Is Evolving and Generating Increased Viral Diversity</article-title>. <source>Frontiers in Microbiology</source>. <year>2021</year><month>Jun</month><day>21</day>;<volume>12</volume>:<fpage>665041</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fmicb.2021.665041</pub-id> eCollection 2021. <?supplied-pmid 34234758?><pub-id pub-id-type="pmid">34234758</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
